Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24250390 | 0.86 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL24595466 | 0.85 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL18616928 | 0.85 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL2638516 | 0.82 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1 | |
| SCHEMBL31174292 | 0.82 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1 | |
| SCHEMBL19676845 | 0.82 | ADRA1D (0.42) | MEN1KMT2ALMNATHRBBLM | |
| SCHEMBL24810740 | 0.82 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL22434096 | 0.82 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL28985637 | 0.82 | POLB (0.60) | MEN1KMT2ALMNAKDM4E | |
| SCHEMBL18678765 | 0.82 | LMNA (0.40) | MEN1KMT2ALMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130673-A1 | POLYMER AND PREPARATION METHOD THEREFOR | 深圳华大生命科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130674-A1 | METHOD FOR PREPARING AMPHIPHILIC POLYMER | 深圳华大生命科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| EP-4010352-B1 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | GYROS PROTEIN TECH AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4219446-A2 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Gyros Protein Technologies AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023012820-A1 | A PROCESS FOR THE PREPARATION OF GRAPIPRANT AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| US-11534427-B2 | Applications of novel thiazole derivative in treating inflammatory bowel diseases | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-3684845-B1 | METHOD OF MODIFYING A POLYIMIDE AND THE POLYIMIDE RESULTING THEREFROM | SHPP GLOBAL TECH BV (NL) | 2022-12-21 | — | — | EP | disclosed |
| US-20220087906-A1 | PHOTOPOLYMERIZATION INITIATOR, PHOTOCURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | MITSUI CHEMICALS, INC. (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3459937-B1 | THIAZOLE DERIVATIVE AND APPLICATIONS | UNIV EAST CHINA SCIENCE & TECH (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-4140698-A | 1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-nitriles | SYNTEX (USA) INC. (US) | 1979-02-20 | — | — | US | disclosed |
| EP-0000649-A1 | 5-substituted-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids | SYNTEX (U.S.A.) INC. (US) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | MEN1 4317/4885KMT2A 2587/4885SMN1; SMN2 155/4885 |
| US-11534427-B2 | Applications of novel thiazole derivative in treating inflammatory bowel diseases | FABP2, SLC10A2, ALPI | MEN1 4844/4885KMT2A 4681/4885SMN1; SMN2 4806/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | MEN1 4317/4885KMT2A 2587/4885SMN1; SMN2 155/4885 |
| US-20220087906-A1 | PHOTOPOLYMERIZATION INITIATOR, PHOTOCURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | PPOX, PRXL2A, RAD51 | MEN1 2798/4885KMT2A 1154/4885SMN1; SMN2 4502/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | MEN1 4882/4885KMT2A 4071/4885SMN1; SMN2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.